Souhaitez-vous accéder aux communiqués récents ?

Oxford, UK and Boston, MA – January 6, 2026 – Sitryx Therapeutics (“Sitryx” or “the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in...

MindRank Initiates Phase III "MOBILE" Trial for MDR-001: an Oral GLP-1RA Small Molecule Engineered with AI

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to...

- Company expects topline data from the study in 2027 WESTLAKE VILLAGE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the...

GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCompany to seek FDA alignment on global Phase 3 program replicating Phase 2b designPhase 3 initiation targeted for...

Agios today announced that its management team is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026

DUBLIN, Jan. 02, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing...

IRVING, Texas, Dec. 31, 2025 (GLOBE NEWSWIRE) -- As 2025 ends, BioNTX reflects on a year—and the close of the first quarter of the 21st century—defined by accelerated growth, expanded engagement,...

-  Arrangements provide increased near-term funding and extend maturity of credit agreement to early 2027 -  Equity settlement mechanisms also agreed for milestone payments and contingent acquisition...

- TrinScreen HIV order signals renewed strength in global HIV testing market - Company also reports a key milestone of Adjusted EBITDA1positive operations in Q3 2025 and expects to achieve strong...